223 related articles for article (PubMed ID: 9617787)
21. Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
Watson E; Wilk S
Psychopharmacologia; 1975 Apr; 42(1):57-6. PubMed ID: 1153623
[TBL] [Abstract][Full Text] [Related]
22. Tetrahydrobiopterin and Parkinson's disease.
Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
[TBL] [Abstract][Full Text] [Related]
23. Biochemical aids in the diagnosis of Parkinson's disease.
Chase TN; Eng N; Gordon EK
Ann Clin Lab Sci; 1976; 6(1):4-10. PubMed ID: 1247283
[TBL] [Abstract][Full Text] [Related]
24. Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
Antkiewicz-Michaluk L; Krygowska-Wajs A; Szczudlik A; Romańska I; Vetulani J
Biol Psychiatry; 1997 Sep; 42(6):514-8. PubMed ID: 9285087
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B
Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926
[TBL] [Abstract][Full Text] [Related]
26. Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
Goldstein DS; Sullivan P; Holmes C; Lamotte G; Lenka A; Sharabi Y
J Neurochem; 2021 Jul; 158(2):554-568. PubMed ID: 33894018
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
Jiménez-Jiménez FJ; Molina JA; Hernánz A; Fernández-Vivancos E; de Bustos F; Barcenilla B; Gómez-Escalonilla C; Zurdo M; Berbel A; Villanueva C
Neurosci Lett; 1999 Aug; 271(1):33-6. PubMed ID: 10471207
[TBL] [Abstract][Full Text] [Related]
28. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
[TBL] [Abstract][Full Text] [Related]
29. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.
Ishibashi K; Kanemaru K; Saito Y; Murayama S; Oda K; Ishiwata K; Mizusawa H; Ishii K
Acta Neurol Scand; 2010 Jul; 122(1):46-51. PubMed ID: 20002007
[TBL] [Abstract][Full Text] [Related]
31. Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease.
Moser A; Scholz J; Nobbe F; Vieregge P; Böhme V; Bamberg H
J Neurol Sci; 1995 Aug; 131(2):183-9. PubMed ID: 7595645
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in CSF biomarkers for Parkinson's disease.
LeWitt P
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S49-51. PubMed ID: 22166453
[TBL] [Abstract][Full Text] [Related]
33. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
Herbert MK; Kuiperij H; Bloem BR; Verbeek MM
J Neurol; 2013 Dec; 260(12):3129-33. PubMed ID: 24122060
[TBL] [Abstract][Full Text] [Related]
34. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
Brashear A; Butler IJ; Hyland K; Farlow MR; Dobyns WB
Ann Neurol; 1998 Apr; 43(4):521-6. PubMed ID: 9546335
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
[TBL] [Abstract][Full Text] [Related]
37. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Davidson DF; Grosset K; Grosset D
Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
[TBL] [Abstract][Full Text] [Related]
38. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
39. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome.
Ueda M; Hamamoto M; Nagayama H; Okubo S; Amemiya S; Katayama Y
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):111-3. PubMed ID: 11413275
[TBL] [Abstract][Full Text] [Related]
40. Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Mash DC; Kopin IJ; Sharabi Y
Parkinsonism Relat Disord; 2017 Feb; 35():88-91. PubMed ID: 28034624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
